Skip to content

Effect of Nebulized Budesonide on Reducing Extubation Failure in Neonates

Comparison of Nebulized Budesonide versus Placebo in Reducing Extubation Failure in Mechanically Ventilated Neonates: A Randomized Double-Blind Clinical Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201222049802N6
Enrollment
94
Registered
2025-05-27
Start date
2025-06-06
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory distress.

Interventions

Intervention 1: Intervention group: Budesonide AstraZeneca Nebulizer (500 micrograms every 12 hours) for 3 days
the first dose is administered immediately after extubation. The drug can be administered undiluted or with 2 ml of 0.9% sodium chloride solution (to bring the total volume to 4 ml). Activate the nebu

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 28 Days

Inclusion criteria

Inclusion criteria: Neonates who are candidates for extubation Duration of Intubation less than one week First etubation session Written consent from parents or legal guardians

Exclusion criteria

Exclusion criteria: Birth at less than 28 weeks of gestation Congenital defects of the respiratory or cardiac system Genetic disorders Neuromuscular disorders

Design outcomes

Primary

MeasureTime frame
Extubation success: defined as the need for reintubation. Timepoint: At 24, 48, 72 hours, and up to one week after extubation. Method of measurement: Record patient file information.;Duration of need for non-invasive respiratory support. Timepoint: From the time of first extubation to discharge. Method of measurement: Number of days required for non-invasive ventilation.;Mortality until discharge from hospital. Timepoint: From the time of hospitalization to the day of death. Method of measurement: Physical examination.;Bronchopulmonary dysplasia. Timepoint: At the age of 36 weeks. Method of measurement: Clinical observation and chest x ray.;Occurrence or worsening of respiratory distress after extubation (stridor, laryngospasm, upper airway obstruction). Timepoint: Up to one week after extubation. Method of measurement: Clinical evaluation.

Secondary

MeasureTime frame
Oral candidiasis. Timepoint: From the time of first extubation to discharge. Method of measurement: Physical examination.;Germinal matrix hemorrhage. Timepoint: From patient admission to hospital discharge. Method of measurement: Brain Sonography.;Patent ductus arteriosus requires treatment. Timepoint: From patient admission to hospital discharge. Method of measurement: Echocardiography.;Positive culture-proven infections. Timepoint: From patient admission to hospital discharge. Method of measurement: Laboratory results.;Duration of hospitalization. Timepoint: At the time of discharge from the hospital. Method of measurement: Count the number of hospitalization days.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsghar Marzban

Zanjan University of Medical Sciences

Drmarzban@zums.ac.ir+98 24 3313 1292

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026